PTC Therapeutics Inc (NAS:PTCT)
$ 36.5 -0.23 (-0.63%) Market Cap: 2.81 Bil Enterprise Value: 2.13 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 68/100

PTC Therapeutics Inc PTC518 Phase 1 Huntington's Disease Program Update Conference Call Transcript

Sep 23, 2021 / 12:00PM GMT
Release Date Price: $39.48 (-9.90%)
Operator

Good day, and thank you for standing by. Welcome to the PTC518 Data Release Conference Call. (Operator Instructions) After the speakers' presentation there'll be a question-and-answer session. (Operator Instructions) Please be advised that today's conference may be recorded.

I would now like to hand the conference over to your speaker today, Kylie O'Keefe, Senior Vice President of Global, Commercial and Corporate Strategy. Please go ahead.

Kylie O;Keefe
PTC Therapeutics, Inc. - VP, Head of Global Strategic Marketing & Business Intelligence

' -

Good morning, everyone, and thank you for joining us. Today we'll be discussing the results of our PTC518 program in Huntington's disease. Joining me on today's call is our Chief Executive Officer, Dr. Stuart Peltz; and our Chief Development Officer, Dr. Matthew Klein. As a reminder, slides are available in the Investors section of the website for you to follow along during the presentation today.

I will now pass the call over to our Chief Executive Officer, Stuart Peltz. Stuart?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot